Comerica Bank’s Royalty Pharma RPRX Stock Holding History

Comerica Bank’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-9,151	Closed	-$356K	–	2324
2021 Q2	$356K	Sell	9,151 -466	-5%	-$19.8K	﹤0.01%	2112
2021 Q1	$419K	Buy	+9,617	New	+$456K	﹤0.01%	2070

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

VCG

Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Comerica Bank's RPRX Position: Q3 2021 in Review

Comerica Bank sold out of Royalty Pharma (RPRX) in Q3 2021, closing a stake of 9,151 shares — an estimated $356K sold.

Comerica Bank first reported a position in RPRX in Q1 2021 and held it in 2 quarters. The position peaked at $419K in Q1 2021. 232 funds tracked by Wall St. Rank hold RPRX as of Q3 2021.

Comerica Bank reported no remaining Royalty Pharma position as of Q3 2021 after selling out during the quarter.
Comerica Bank sold 9,151 Royalty Pharma shares in Q3 2021, an estimated $356K.
Comerica Bank first reported a position in Royalty Pharma in Q1 2021 and held it in 2 quarters.
Comerica Bank's Royalty Pharma position peaked at $419K in Q1 2021.
232 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2021.

Based on Comerica Bank's 13F filing for Q3 2021, filed 22 Nov 2021.